We serve Chemical Name:3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride CAS:54945-02-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride
CAS.NO:54945-02-7
Synonyms:1h-1,2,4-triazole-1-carbonyl chloride,2,3-dihydro-5-methyl-3-oxo
Molecular Formula:C4H4ClN3O2
Molecular Weight:161.54600
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:68.01000
Exact Mass:160.99900
LogP:0.49900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 1h-1,2,4-triazole-1-carbonyl chloride,2,3-dihydro-5-methyl-3-oxo chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1h-1,2,4-triazole-1-carbonyl chloride,2,3-dihydro-5-methyl-3-oxo physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1h-1,2,4-triazole-1-carbonyl chloride,2,3-dihydro-5-methyl-3-oxo Use and application,1h-1,2,4-triazole-1-carbonyl chloride,2,3-dihydro-5-methyl-3-oxo technical grade,usp/ep/jp grade.
Related News: On Friday, the US Association of Flight Attendants — which represents 50,000 flight attendants across 20 airlines — called on the government to work with airlines to discontinue all travel to China until the spread of coronavirus is contained. 3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride manufacturer Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. 3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride supplier On Friday, the US Association of Flight Attendants — which represents 50,000 flight attendants across 20 airlines — called on the government to work with airlines to discontinue all travel to China until the spread of coronavirus is contained. 3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride vendor We found over half the products we tested contained elevated fluorine levels,” Bruton said.
The cosmetic categories that had the highest percentage of 213 high fluorine products were foundations (63%), eye products (58%), mascaras (47%), and lip products (55%), the study found.
Even more concerning was that cosmetics containing high levels of fluorine more often than not failed to disclose any PFAS chemicals on their labels, Bruton noted.
Further analysis of 29 cosmetics with high fluorine levels revealed that they contained between four and 13 specific PFAS chemicals, researchers found. However, only 1 of the 29 products listed PFAS as an ingredient on the product label.
“Even if a consumer is doing their due diligence and trying to avoid harmful chemicals by reading labels, our work is showing that these harmful chemicals are often not disclosed,” Bruton said.
Despite this, Bruton recommends that consumers who want to limit their exposure to PFAS read the labels anyway, to at least avoid products where the chemicals are accurately listed.
High levels of fluorine were frequently found in products advertised as “long-lasting” and “wear-resistant,” which could provide another clue for discerning consumers.
But in the end, there’s not much consumers can do to solve the problem.
“It’s important that the government step up to regulate ingredients in cosmetics with more stringency,” Bruton said. “It’s also time the cosmetics industry steps up and begins efforts to move away from this class of chemicals. 3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride factory This suspension applies to all dogs, including puppies, emotional support dogs, and dogs that traveled out of the United States and are returning from a high-risk country,” the CDC said in a statement.
The agency said dog rescue missions, imports from dog breeders and people bringing in pets will be affected by the decision, CNN reported.
“If these dogs coming from high-risk countries haven’t been properly vaccinated, there is a risk they could bring it into the country,” Dr. Emily Pieracci, a veterinary medical officer in CDC’s Division of Global Migration and Quarantine, told CNN.
“I think it is important to stress that this is a temporary suspension. We recognize that this is not the long-term solution,” she said, with the initial suspension likely to be 12 months.
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
“We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly.”
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from four FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, Rezipres®, and Alaway® Preservative Free, and has five additional products that have been submitted to the FDA.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives.
These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made.
Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were identified in individuals before the first cases of infection were recognized, according to a study published online June 15 in Clinical Infectious Diseases.
Keri N. Althoff, Ph.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues aimed to identify individuals with SARS-CoV-2 antibodies in the early weeks of the U.S. pandemic among All of Us participants in all 50 U.S. states who provided blood specimens from Jan. 2 to March 18, 2020.
Participants were considered seropositive if they tested positive for SARS-CoV-2 immunoglobulin G antibodies with the Abbott or EUROIMMUN assays in a sequential testing algorithm.
The researchers found that the estimated sensitivity and specificity of Abbott were100 and 99.5 percent, respectively, and the estimated sensitivity and specificity of EUROIMMUN were 90.7 and 99.7 percent, respectively.
For the sequential testing algorithm used in the study, the net sensitivity and specificity were 90.7 and 100.0 percent, respectively. Overall, nine of the 24,079 study participants with blood specimens from Jan. 2 to March 18, 2020, were seropositive; seven of these were seropositive prior to the first confirmed case in the states of Illinois, Massachusetts, Wisconsin, Pennsylvania, and Mississippi.
“This study contributes to the evidence of low-level circulation of SARS-CoV-2 in many states at the start of the U.S. epidemic,” the authors write. “Future pandemic management should carefully consider the impact of epidemiologic links in testing recommendations and reduce testing restrictions as early as possible.
The cosmetic categories that had the highest percentage of 213 high fluorine products were foundations (63%), eye products (58%), mascaras (47%), and lip products (55%), the study found.
Even more concerning was that cosmetics containing high levels of fluorine more often than not failed to disclose any PFAS chemicals on their labels, Bruton noted.
Further analysis of 29 cosmetics with high fluorine levels revealed that they contained between four and 13 specific PFAS chemicals, researchers found. However, only 1 of the 29 products listed PFAS as an ingredient on the product label.
“Even if a consumer is doing their due diligence and trying to avoid harmful chemicals by reading labels, our work is showing that these harmful chemicals are often not disclosed,” Bruton said.
Despite this, Bruton recommends that consumers who want to limit their exposure to PFAS read the labels anyway, to at least avoid products where the chemicals are accurately listed.
High levels of fluorine were frequently found in products advertised as “long-lasting” and “wear-resistant,” which could provide another clue for discerning consumers.
But in the end, there’s not much consumers can do to solve the problem.
“It’s important that the government step up to regulate ingredients in cosmetics with more stringency,” Bruton said. “It’s also time the cosmetics industry steps up and begins efforts to move away from this class of chemicals. 3-methyl-5-oxo-1H-1,2,4-triazole-2-carbonyl chloride factory This suspension applies to all dogs, including puppies, emotional support dogs, and dogs that traveled out of the United States and are returning from a high-risk country,” the CDC said in a statement.
The agency said dog rescue missions, imports from dog breeders and people bringing in pets will be affected by the decision, CNN reported.
“If these dogs coming from high-risk countries haven’t been properly vaccinated, there is a risk they could bring it into the country,” Dr. Emily Pieracci, a veterinary medical officer in CDC’s Division of Global Migration and Quarantine, told CNN.
“I think it is important to stress that this is a temporary suspension. We recognize that this is not the long-term solution,” she said, with the initial suspension likely to be 12 months.
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that the U.S. Food and Drug Administration (FDA) has approved Rezipres (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anesthesia.
“We are excited to see the approval of Rezipres, which is now our second FDA-approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “This innovative sulfite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly.”
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from four FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, Rezipres®, and Alaway® Preservative Free, and has five additional products that have been submitted to the FDA.
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives.
These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made.
Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies were identified in individuals before the first cases of infection were recognized, according to a study published online June 15 in Clinical Infectious Diseases.
Keri N. Althoff, Ph.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues aimed to identify individuals with SARS-CoV-2 antibodies in the early weeks of the U.S. pandemic among All of Us participants in all 50 U.S. states who provided blood specimens from Jan. 2 to March 18, 2020.
Participants were considered seropositive if they tested positive for SARS-CoV-2 immunoglobulin G antibodies with the Abbott or EUROIMMUN assays in a sequential testing algorithm.
The researchers found that the estimated sensitivity and specificity of Abbott were100 and 99.5 percent, respectively, and the estimated sensitivity and specificity of EUROIMMUN were 90.7 and 99.7 percent, respectively.
For the sequential testing algorithm used in the study, the net sensitivity and specificity were 90.7 and 100.0 percent, respectively. Overall, nine of the 24,079 study participants with blood specimens from Jan. 2 to March 18, 2020, were seropositive; seven of these were seropositive prior to the first confirmed case in the states of Illinois, Massachusetts, Wisconsin, Pennsylvania, and Mississippi.
“This study contributes to the evidence of low-level circulation of SARS-CoV-2 in many states at the start of the U.S. epidemic,” the authors write. “Future pandemic management should carefully consider the impact of epidemiologic links in testing recommendations and reduce testing restrictions as early as possible.
